Eli Lilly Captures Over 30% of New U.S. Patients on Oral Weight-Loss Medications
An Eli Lilly executive reported that the company has secured more than 30% of new patients in the United States using oral weight-loss medications, highlighting strong market adoption for its obesity treatment Foundayo (orforglipron). The drug was launched in early April and entered a competitive space dominated by Novo Nordisk's offerings. This rapid uptake underscores growing demand for effective non-invasive treatments to address obesity. Lilly’s success with Foundayo reflects the increasing importance of oral alternatives as patients seek easier-to-manage treatment options compared to injectables or implants. The pharmaceutical sector is witnessing a surge in innovation and competition, driven by rising global health concerns around obesity-related conditions such as diabetes and cardiovascular disease.
Topics: Eli Lilly Foundayo Novo Nordisk Obesity Drugs Orforglipron